Literature DB >> 16357786

New insight into the pathophysiology of lipid abnormalities in type 2 diabetes.

B Vergès1.   

Abstract

Lipid abnormalities in patients with type 2 diabetes are likely to play an important role in the development of atherogenesis. These lipid disorders include not only quantitative but also qualitative abnormalities of lipoproteins which are potentially atherogenic. The main quantitative abnormalities are increased triglyceride levels, related to an augmented hepatic production of VLDL and a reduction of both VLDL and IDL catabolism, and decreased HDL-Cholesterol levels due to an accelerated HDL catabolism. The main qualitative abnormalities include large VLDL particles (VLDL1), relatively rich in triglycerides, small dense LDL particles, increase in triglyceride content of LDL and HDL, glycation of apolipoproteins and increased susceptibility of LDL to oxidation. Moreover, although plasma LDL-cholesterol level is usually normal in type 2 diabetic patients, LDL particles show significant kinetic abnormalities, such as reduced turn-over, which is potentially harmful. The pathophysiology of lipid abnormalities in type 2 diabetes is not yet totally explained. However, insulin resistance and the "relative" insulin deficiency, observed in patients with type 2 diabetes, are likely to play a crucial role since insulin has an important function in the regulation of lipid metabolism. In addition, it is not excluded that adipocytokines, such as adiponectin, could play a role in the pathophysiology of lipid abnormalities in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16357786     DOI: 10.1016/s1262-3636(07)70213-6

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  29 in total

1.  Characterization of metabolic interrelationships and in silico phenotyping of lipoprotein particles using self-organizing maps.

Authors:  Linda S Kumpula; Sanna M Mäkelä; Ville-Petteri Mäkinen; Anna Karjalainen; Johanna M Liinamaa; Kimmo Kaski; Markku J Savolainen; Minna L Hannuksela; Mika Ala-Korpela
Journal:  J Lipid Res       Date:  2009-09-05       Impact factor: 5.922

Review 2.  Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus.

Authors:  Surapon Tangvarasittichai
Journal:  World J Diabetes       Date:  2015-04-15

Review 3.  Are thiazolidinediones good or bad for the heart?

Authors:  Angela M Taylor; Coleen A McNamara
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

4.  Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.

Authors:  B Vergès; E Florentin; S Baillot-Rudoni; S Monier; J M Petit; D Rageot; P Gambert; L Duvillard
Journal:  Diabetologia       Date:  2008-06-05       Impact factor: 10.122

Review 5.  Fatty liver, insulin resistance, and dyslipidemia.

Authors:  Martin Adiels; Marja-Riitta Taskinen; Jan Borén
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

6.  Enhanced complement activation is part of the unfavourable cardiovascular risk profile in South Asians.

Authors:  M A Siezenga; P K Chandie Shaw; R N van der Geest; T E Mollnes; M R Daha; T J Rabelink; S P Berger
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

7.  Regulation of SREBP-Mediated Gene Expression.

Authors:  Zhao Xiaoping; Yang Fajun
Journal:  Sheng Wu Wu Li Hsueh Bao       Date:  2012

8.  Nocturnal activation of melatonin receptor type 1 signaling modulates diurnal insulin sensitivity via regulation of PI3K activity.

Authors:  Sharon Owino; Aida Sánchez-Bretaño; Cynthia Tchio; Erika Cecon; Angeliki Karamitri; Julie Dam; Ralf Jockers; Giuseppe Piccione; Hye Lim Noh; Taekyoon Kim; Jason K Kim; Kenkichi Baba; Gianluca Tosini
Journal:  J Pineal Res       Date:  2018-01-09       Impact factor: 13.007

Review 9.  The regulation of ApoB metabolism by insulin.

Authors:  Mary E Haas; Alan D Attie; Sudha B Biddinger
Journal:  Trends Endocrinol Metab       Date:  2013-05-27       Impact factor: 12.015

10.  Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes.

Authors:  Bruno Vergès; Emmanuel Florentin; Sabine Baillot-Rudoni; Jean-Michel Petit; Marie Claude Brindisi; Jean-Paul Pais de Barros; Laurent Lagrost; Philippe Gambert; Laurence Duvillard
Journal:  J Lipid Res       Date:  2009-01-22       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.